Encore Medical in Berlin - 500 Beiträge pro Seite

[ajuga]

Encore Medicals (ENMC) letzter US-Kurs lag bei 4,92 $. In Berlin (910210) gibt es die Aktien für 5,05 € (echter Briefkurs), obwohl die Aktie umgerechnet 5,60 € wert ist.

Ich bin nicht der Verkäufer. Nachkaufen tue ich nicht, weil meine Position in Encore zu groß werden würde.

Also falls jemand die Abweichung ausnutzen will...

[ajuga]

Encore Medical Reports Record Sales, Improved Earnings for 2001; Core Implant Growth and Acquisition Strategy Implementation Show Results

3/4/2002 8:01:00 AM

AUSTIN, Texas, Mar 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- Encore Medical Corporation (ENMC) today released its results for the fourth quarter and full 2001 fiscal year. These results highlight the strong sales growth that Encore has accomplished during the year, both as a consequence of significant growth in its core business line of orthopedic implants, as well as from initial results from the acquisition strategy that it initiated during 2001.

Encore reported record sales for 2001 of $42.7 million compared to $30.1 million in 2000. This represents a 42% increase in sales from year to year. While approximately $8.9 million of this increase was a result of the July acquisition of the orthopedic soft goods, patient safety device and pressure care product lines from Kimberly-Clark Corporation, the sales of orthopedic implants increased to $33.8 million, a 12% increase over 2000. Most importantly, the increase in implant sales was a result of domestic implant sales showing a 28% increase in 2001 over 2000. Encore, as previously announced, concentrated during 2001 on building its United States sales force, while de-emphasizing international sales efforts. In fact, Encore`s domestic implant business showed double-digit growth in every product line during 2001. Leading this list of product line increases, spine implant sales increased an impressive 200% over 2000.

The results for the entire year are mirrored in the results for the fourth quarter of 2001. Sales for the fourth quarter were $12.3 million, a 66% increase over sales of $7.4 million for the same quarter of 2000. Orthopedic soft goods, patient safety devices and pressure care products, a third quarter product line acquisition for Encore, reported fourth quarter 2001 sales of $4.0 million. Orthopedic implant sales increased 12% over the fourth quarter of 2000. Domestic implant sales increased 27%, with spine implant sales increasing 218% over spine sales in the fourth quarter of 2000.

Kenneth W. Davidson, CEO and President of Encore Medical Corporation, in commenting on 2001 results, stated, "This past year we launched Encore down its new road. We started by having a strong year of growth in our implant product lines. We added to this with the first of our acquisitions that we intend to make to broaden our product offerings providing a full continuum of care to patients of orthopedic professionals. As a result, we have achieved record sales. We have quickly followed last year`s strong results with the significant acquisition of Chattanooga Group, Inc. This puts us on track to have sales of over $100 million in 2002, which will result in further quarterly and annual record sales for Encore."

Corresponding to the strong increase in sales for 2001 over 2000, there was a significant improvement in the bottom line. For 2001, net income for the year equaled $549,000, or $0.03 per diluted share, compared to a loss of $3.3 million or $0.36 per diluted share for the same time period in 2000. Even given this improvement, the net income for 2001 would have been higher if it were not negatively impacted by several specific non-recurring charges, totaling $1.6 million, recorded in the second quarter of 2001. These charges were primarily associated with the issuance of the Series A Preferred Stock. When analyzing 2000 results, it should be noted that the net loss for 2000 included charges for additional reserves for inventory of $4.2 million (included in cost of goods sold) and non-recurring charges of $2.0 million, both of which occurred in the fourth quarter of 2000. Excluding these non- recurring charges for both 2001 and 2000, operating income increased approximately 49% during 2001. Notwithstanding the positive results for net income in 2001, net loss attributable to common stock was $3.2 million, or $0.34 per diluted share, as a result of including a non-cash accounting charge of $3.7 million related to the beneficial conversion privilege associated with the June 2001 issuance of Series A Preferred Stock.

The annual results were also indicative of the fourth quarter results. For the quarter, Encore reported net income of $183,000, or $0.01 per diluted share, compared to a net loss of $4.2 million, or ($0.47) per diluted share, for the fourth quarter of 2000. Net loss for 2000 included charges stemming from increasing additional reserves for inventory and non-recurring charges. To put results on a comparable basis, without these charges, net income for the fourth quarter of 2001 increased to $183,000 versus a loss of $199,000 for the same period of 2000.

August Faske, Chief Financial Officer of Encore, stated, "In addition to our sales increase, we made great strides to increase the profits and operating efficiencies of Encore during 2001. Not only did our bottom line increase, but our cash flow was significantly stronger in 2001 when compared to 2000. Cash flow from operations improved $11.7 million during 2001 with key contributions coming from operating income and inventory reductions. While there is always room for improvement, we believe that the path that we are on will continue to show increasingly better results in the future."

Encore Medical Corporation, based in Austin, Texas, designs, manufactures and markets orthopedic total joint, trauma and spinal implants around the world. It also offers a complete line of orthopedic soft goods, patient safety devices, and pressure care products. It recently acquired Chattanooga Group, Inc., the leading manufacturer and distributor of orthopedic rehabilitation equipment in the United States. Both Encore and Chattanooga are known for producing high quality, innovative products and continuing to develop new products to meet the needs of the orthopedic community. For more information, visit www.encoremed.com .

[ajuga]

ENMC NASDAQ:



ENMC BERLIN:

[Push Daddy]

danke für den hinweis, waren aber nur 45 stück, hat sich also faktisch nich gelohnt. bin seit november drin

[elcommandante]

Das Unternehmen is ja nich schlecht, und der Kurs-Bonus auch, aber versuch mal bei den Umsätzen in Berlin reinzukommen....

Trade on!!!

El Commandante

[ajuga]

@Push Daddy

Ich bin seit Ende Dezember drin und denke noch lange nicht ans verkaufen. Der Aufwärtstrend kann ENMC noch locker an die 10 Dollar ranbringen.


Ich habe auf den Briefkurs in Berlin aufmerksam gemacht, weil ich mir einen aktiveren Handel in Deutschland wünsche. Allerdings muss ich gestehen, dass ich selbst an der NASDAQ rein bin (knapp unter 3 Dollar). Im letzten Jahr gab es nämlich nur 2 oder 3 Preis-Feststellungen in Berlin. Anfang diesen Jahres hatte sich das schon gebessert.
Jetzt konnte ich jedoch nicht kaufen, weil ich gerade keine Barreserven mehr zur Verfügung habe. Außerdem soll eine Position ja nicht zu groß werden.

Auf zur 10 Dollar - Marke!

ajuga

[ajuga]

Encore Medical Starts 2002 With Record Sales Growth EBITDA Grows 64%

4/29/2002 8:04:00 AM

AUSTIN, Texas, Apr 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- Encore Medical Corporation (ENMC) today announced sales of $19.4 million for the first quarter of 2002, an increase of 122% over the results Encore obtained during the first quarter of 2001. In addition to the strong growth in sales, EBITDA increased 64% during the first quarter of 2002 over the first quarter of 2001, from $1.4 million to $2.3 million. These results highlight the progress of Encore`s recent strategy in terms of building its revenues and cash flow, achieving critical mass and expanding its product offerings.


Following the strong sales performance, operating income increased 30% to $836,000 for the first quarter of 2002 compared to $644,000 for the first quarter of 2001. This was even after the inclusion of over $70,000 of amortization expense related to identifiable intangible assets acquired as part of the Chattanooga Group acquisition, which purchase is a part of its strategy that is further discussed below. In meeting Encore`s goal of returning to profitability during 2002 after having lost money in both 2000 and 2001, Encore achieved net income of $35,000 even after taking into account the increased interest and financing expenses related the Chattanooga Group transaction. This compares to net income of $228,000 in 2001. Earnings per share for first quarter of 2002 were breakeven, compared to $0.02 on a diluted basis for the first quarter of 2001.

Encore has realized that the orthopedic medical community is progressing to a synergist relationship between orthopedic surgeons and sports medicine professionals. Therefore, to take advantage of this industry trend, Encore has embarked on the process of broadening its product platforms to encompass a larger array of orthopedic medical products. It expects that it will continue to grow its surgical implant business, primarily in the United States, while at the same time building its other orthopedic platforms to become a mid-tier, diversified orthopedic company producing between $200 and $300 million in sales in the next several years. It anticipates being able to accomplish this top line revenue growth while growing its cash flow, returning to profitability during 2002 and building on those profits in the following years. Encore recognizes that its growth will be both as a result of internal growth as well as by consummating accretive acquisitions.

Towards those objectives, Encore took some significant steps during the first quarter of 2002. It increased its domestic sales of surgical products and closed its largest acquisition to date during February, when it acquired Chattanooga Group, Inc. The results of these moves have begun to already be shown on the top line, as well as flowing through to increases in the EBITDA being generated by the Company.

Encore`s newest division, Chattanooga Group, which designs, manufactures and distributes rehabilitation products, contributed $6.5 million to first quarter 2002 sales in the seven weeks since the February 8, 2002 acquisition date. This compares to its 2001 sales during the same period of $6.1 million, an increase of over 6%. Orthopedic soft goods division sales, which stem from a July 2001 purchase of the orthopedic soft goods, patient safety device and pressure care product lines from Kimberly-Clark Corporation, added another $4.7 million to first quarter 2002 results.

In the surgical division, namely total joint and spinal implants, and trauma products, a record quarter was achieved in domestic sales of Encore`s surgical products. Led by a significant increase in spine sales, domestic sales grew 15% to $7.1 million compared to $6.2 million in 2001. As Encore has been focusing on growing its domestic sales, as opposed to expending resources on building an international sales force, the $1.4 decrease in international sales was expected. This resulted in an overall decline in surgical product sales of $500,000 or 6% compared to the first quarter of 2001. The decline in international sales from the levels of 2001 is expected to continue during the rest of 2002.

On a pro forma basis (assuming that both the Chattanooga Group acquisition had been done and produced $6.1 million of sales and that the soft goods purchase had been consummated at the beginning of 2001 and produced $4.4 million of sales), overall sales, excluding the international sales component of surgical products from both years, would have produced sales growth of 10%, from $16.7 million in 2001 to $18.3 million in 2002.

"We are pleased with the milestones we have achieved this quarter. The completion of our second acquisition has provided Encore with a solid foundation for continued growth and expansion. We are excited with the expanded product line and the fact that every division, except international surgical sales showed strong growth, even in this year of transition, said Kenneth W. Davidson, CEO and President of Encore Medical Corporation. "We have focused on building our domestic surgical product sales force and these efforts are beginning to pay off. We set out to grow and the Chattanooga acquisition is a significant event in Encore`s progress."

Encore Medical Corporation, based in Austin, Texas, designs, manufactures and markets orthopedic total joint, trauma and spinal implants around the world. It also offers a complete line of orthopedic soft goods, patient safety devices, and pressure care products. It recently acquired Chattanooga Group, Inc., the leading manufacturer and distributor of orthopedic rehabilitation equipment in the United States. Both Encore and Chattanooga are known for producing high quality, innovative products and continuing to develop new products to meet the needs of the orthopedic community. For more information, visit http://www.encoremed.com .